SCHEDULE 13G: Hudson Bay Capital Management Discloses 9.98% Stake in Psyence Biomedical Ltd.
Beneficial Ownership Filing
Hudson Bay Capital Management LP and Sander Gerber have disclosed a beneficial ownership of 9.98% in Psyence Biomedical Ltd., totaling 380,000 common shares.
Summary
- Hudson Bay Capital Management LP and Mr. Sander Gerber, collectively referred to as "Reporting Persons," have filed a Schedule 13G.
- The filing indicates beneficial ownership of 380,000 common shares of Psyence Biomedical Ltd., representing 9.98% of the company's outstanding common shares.
- The shares were acquired on December 24, 2024, as part of an offering described in Psyence Biomedical Ltd.'s Prospectus filed on December 31, 2024.
- The calculation of the 9.98% ownership is based on an aggregate of 3,807,128 common shares outstanding, which includes 3,427,128 shares outstanding as of December 17, 2024, plus the 380,000 shares purchased by the Reporting Persons.
- Hudson Bay Capital Management LP serves as the investment manager to Hudson Bay Master Fund Ltd., in whose name the securities are held.
- Mr. Gerber, as the managing member of Hudson Bay Capital GP LLC (the general partner of the Investment Manager), disclaims beneficial ownership of these securities.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing (Schedule 13G) disclosing a passive ownership stake. It does not contain information that would inherently convey positive or negative sentiment about the company's performance or outlook, but rather reflects an investment decision by a third party.
Future Outlook
NA
Industry Context
This filing indicates a significant passive investment by a hedge fund in a biomedical company. Such disclosures are common for institutional investors crossing ownership thresholds and typically reflect an investment decision rather than operational or strategic changes within the company itself. It suggests that the investor sees value in Psyence Biomedical Ltd.'s common shares.
Stakeholder Impact
- Shareholders: The disclosure of a significant institutional investor taking a nearly 10% stake could be viewed positively, signaling confidence in the company, or it could raise questions about potential future intentions, though this filing indicates a passive investment.
Key Dates
| Date | Description |
|---|---|
| 2024-12-17 | Date as of which 3,427,128 common shares of Psyence Biomedical Ltd. were reported outstanding in the company's Prospectus. |
| 2024-12-24 | Date when Reporting Persons purchased 380,000 common shares in the offering. |
| 2024-12-31 | Date of the event which requires the filing of this statement; also the filing date of Psyence Biomedical Ltd.'s Prospectus pursuant to Rule 424(b)(3). |
| 2025-02-10 | Date the Schedule 13G was signed by Hudson Bay Capital Management LP and Sander Gerber. |
Keywords
Psyence Biomedical Ltd., Hudson Bay Capital Management LP, Sander Gerber, Schedule 13G, Beneficial Ownership, Common Shares, Investment Management, SEC Filing, Equity Stake
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.